Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $92

Benzinga Newsdesk www.benzinga.com Negative 52.2%

Neg 52.2% Neu 0% Pos 0%

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $95 to $92.